Professur für Innere Medizin (Nephrologie und Hypertensiologie)

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial (2020) Perkovic V, Toto R, Cooper ME, Mann J, Rosenstock J, Mcguire DK, Kahn SE, et al. Journal article Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial (2020) Buse JB, Bain SC, Mann J, Nauck MA, Nissen SE, Pocock S, Poulter NR, et al. Journal article Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease (2020) Mann J, Fonseca VA, Poulter NR, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Mosenzon O Journal article Cardiovascular Mortality Can Be Predicted by Heart Rate Turbulence in Hemodialysis Patients (2020) Braunisch MC, Mayer CC, Bauer A, Lorenz G, Haller B, Rizas KD, Hagmair S, et al. Journal article Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials (2020) Mann J, Hansen T, Idorn T, Leiter LA, Marso SP, Rossing P, Seufert J, et al. Journal article After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy (2020) Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, et al. Journal article Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials (2020) Verma S, Bain SC, Honoré JB, Mann J, A. Nauck M, E. Pratley R, Rasmussen S, et al. Journal article Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial (2020) Mosenzon O, Bain SC, Heerspink HJL, Idorn T, Mann J, Persson F, Pratley RE, et al. Journal article Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER (2019) Perkovic V, Bain SC, Bakris G, Buse JB, Gondolf T, Idorn T, Lausvig N, et al. Conference contribution Impact of microvascular disease on cardiorenal outcomes in type 2 diabetes: an analysis from the LEADER and SUSTAIN 6 clinical trials (2019) Zinman B, Verma S, Bain SC, Honore JB, Mann J, Nauck MA, Pratley R, et al. Conference contribution